JOHNSON & JOHNSON — Director's Dealing 2022

Feb 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2022-02-14

Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-14	Common Stock	M	3297.0000	$0.0000	Acquired	118423.0010	Direct
2022-02-14	Common Stock	F	1190.0000	$168.8500	Disposed	117233.0010	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-14	Restricted Share Units	$	M	3297.0000	Disposed		Common Stock (3297.0000)	Direct

Footnotes

F1: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.

F2: Shares withheld for payment of taxes upon vesting of Restricted Share Units.